Podcasts about Journal club

Send us a textDopamine versus epinephrine for neonatal septic shock: an open labeled, randomized controlled trial. Singh G, Bhaskar V, Batra P, Gupta P.J Perinatol. 2025 Aug 28. doi: 10.1038/s41372-025-02399-7. Online ahead of print.PMID: 40877444EBNEO Commentary: Review of the 'Norepinephrine Versus Dopamine for Septic Shock in Neonates: A Randomised Controlled Trial'. Altit G.Acta Paediatr. 2025 Jul 23. doi: 10.1111/apa.70241. Online ahead of print.PMID: 40698742 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textCord red blood cell transfusions for severe retinopathy in preterm neonates in Italy: a multicenter randomized controlled trial. Teofili L, Papacci P, Pellegrino C, Dani C, Cresi F, Remaschi G, Ansaldi G, Giannantonio C, Campagnoli MF, Vania B, Fabbri M, de Vera d' Aragona RP, Molisso A, Beccastrini E, Dragonetti A, Pasciuto T, Gabbriellini S, Baroni S, Serrao F, Purcaro V, Raffaeli G, Villa S, Prati D, Mondello I, Falcone A, Patti ML, Boggini T, Bergamaschi P, Lepore D, Franco FGS, Orazi L, Mozzetta I, Baldascino A, Valentini CG, Locatelli E, Albiani R, Besso FG, Cantone GV, Coscia A, Trimarchi A, Cavallaro G, Ghirardello S, Vento G.EClinicalMedicine. 2025 Aug 13;87:103426. doi: 10.1016/j.eclinm.2025.103426. eCollection 2025 Sep.PMID: 40838199 Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textOutcomes of Preterm Infants Born at 22 to 23 Weeks' Gestation in 11 International Neonatal Networks. Isayama T, Norman M, Kusuda S, Reichman B, Lehtonen L, Lui K, Adams M, Vento Torres M, Filippi L, Battin M, Guinsburg R, Modi N, Håkansson S, Klinger G, de Almeida MF, Helenius K, Bassler D, Su YC, Shah PS; International Network for Evaluation of Outcomes (iNeo) Investigators.JAMA Pediatr. 2025 Aug 25:e252958. doi: 10.1001/jamapediatrics.2025.2958. Online ahead of print.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textRespiratory Targets Associated With Lung Aeration During Delivery Room Resuscitation of Preterm Neonates. Rub DM, Hsu JY, Weinberg DD, Felix M, Nadkarni VM, Te Pas AB, Kuypers KLAM, Davis PG, Ratcliffe SJ, Kirpalani HM, Foglia EE.JAMA Pediatr. 2025 Aug 11:e252521. doi: 10.1001/jamapediatrics.2025.2521. Online ahead of print.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textAtropine Versus Placebo for Neonatal Nonemergent Intubation: A Randomized Clinical Trial. Afifi J, El-Naggar W, Hatfield T, Sandila N, Baier J, Narvey M.J Pediatr. 2025 Jul 9;286:114719. doi: 10.1016/j.jpeds.2025.114719. Online ahead of print.PMID: 40645282Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textScreening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia: when, how often and does it matter? Gentle SJ, Carlo WA, Ambalavanan N.Arch Dis Child Fetal Neonatal Ed. 2025 Sep 5:fetalneonatal-2024-328405. doi: 10.1136/archdischild-2024-328405. Online ahead of print.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textContinuous glucose monitoring in a neonate with hyperinsulinemic hypoglycemia and ABCC8 gene mutation. Iwańczyk P, Majewska A, Issat T, Hoffman-Zacharska D, Krajewski P, Lipska-Karpińska K.Endocrinol Diabetes Metab Case Rep. 2025 Jun 5;2025(2):e250002. doi: 10.1530/EDM-25-0002. Print 2025 Apr 1.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this week's Journal Club, Ben and Daphna review several recent neonatal studies with direct implications for practice.They begin with the BORN trial from Italy, which investigated whether transfusing preterm infants with cord blood–derived red blood cells, rather than adult donor blood, could reduce severe retinopathy of prematurity (ROP). While the intention-to-treat analysis showed no difference, per-protocol findings suggest potential benefits that warrant larger trials.Next, they review a large international cohort study of outcomes in infants born at 22–23 weeks, highlighting striking variability in survival and morbidity across networks, with Japan showing the highest survival rates.The EBNeo segment features Dr. Gabriel Altit discussing an Indian randomized trial comparing norepinephrine vs. dopamine as first-line therapy for neonatal septic shock. Although primary outcomes were similar, norepinephrine showed some favorable metabolic and perfusion markers.The hosts then cover a delivery room resuscitation study identifying expiratory tidal volumes of 4–5 ml/kg as key for successful lung aeration, a Canadian trial of atropine for neonatal intubation, and a retrospective study from Alabama on optimal timing and frequency of pulmonary hypertension screening in BPD.The episode concludes with a case report on the use of continuous glucose monitoring in a neonate with congenital hyperinsulinism.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Jesse Selber, MD, discuss the following articles from the September 2025 issue: “Robotic Nipple-Sparing Mastectomy and Breast Reconstruction with Profunda Artery Perforator Flaps” by Haddock, Teotia, and Farr. Read the article for FREE: https://bit.ly/SPrNSM_PAPflaps Special guest, Jesse Selber, MD, was most recently the Acting Chair, the Director of Clinical Research and Professor in the Department of Plastic Surgery at the University of Texas MD Anderson Cancer Center. Currently, he is a Physician Executive and the Surgery Service Line Chief of Beaumont, where he also serves as Professor of Plastic Surgery. In this role, Dr. Selber is responsible for all surgical activities within the Beaumont System, including 8 hospitals overseeing 2000 surgeons. Dr. Selber completed surgery residency at the University of Pennsylvania and fellowship in Microvascular Reconstructive Surgery at MD Anderson Cancer Center. Dr. Selber's clinical practice is exclusively complex cancer reconstruction. He is a surgical innovator, developing numerous techniques, and author of the only robotic plastic surgery textbook.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Los artículos que se tratan en el episodio de hoy están listados aquí: Legge, N., Schneuer, F. J., Shand, A. W., Fitzgerald, D., Popat, H., & Nassar, N. (2025). Educational Performance of Extremely Preterm Infants in Primary School. Pediatrics, 156(1), e2024069425. https://doi.org/10.1542/peds.2024-069425Dudeja, S., Saini, S. S., Sundaram, V., Dutta, S., Sachdeva, N., & Kumar, P. (2025). Early hydrocortisone versus placebo in neonatal shock- a double blind Randomized controlled trial. Journal of perinatology : official journal of the California Perinatal Association, 45(3), 342–349. https://doi.org/10.1038/s41372-025-02222-3Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal.Soy tu host, Maria Flores Cordova, MD.Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos.No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comSíguenos en nuestras redes:Twitter: @incubadorapodInstagram: @laincubadorapodcastCreado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org  Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comSíguenos en nuestras redes:Twitter: @incubadorapodInstagram: @laincubadorapodcast Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

Join us for the September edition of the Simulcast Journal Club, hosted by Vic Brazil and Ben Symon. In this episode: Adapting simulating across cultural contexts, ‘Choosing Wisely' for sensible sim, Video assisted simulation reflection – for teachers!, and simulation in Italy.    And HOT OFF THE PRESS…  The AMEE conference Simulation Journal Club was on last week. We reviewed the 4 shortlisted papers on Simulcast with Rune Del Jessen and Gabe Reedy a few weeks ago. The event went well, with standing room only at the presentation of papers in Barcelona. And the winner is …   “I Hate Sim!”—Using psychotherapeutic concepts to help educators attend to challenging states of mind during simulation prebriefs.by Drake G, Drewek K.   Congratulations!    The September papers  Charnetski MD, Asoodar M, Wawersik D, van Mook W. Navigating cultural landscapes: a thematic analysis of home faculty experiences in transborder simulation curriculum development and adaptation. BMC Med Educ. 2025;25:888.   Monteiro S, Sibbald M, Beecroft J, Bhanji F, Caners K, Chen R, et al. Choosing wisely for simulation-based learning in health professions education. Med Sci Educ. 2025.   Levin O. ‘Reflecting on every move': the role of video in simulation-based learning for teacher education. Eur J Teach Educ. 2025.   Ingrassia PL, Barelli A, Benedetti E, Bressan S, Carenzo L, D'Agostino F, et al. A national position paper for the strategic development of healthcare simulation in Italy. J Patient Saf. 2025.     Another great month on Simulcast.  Happy listening    

Send us a textBem-vindos a mais um episódio do Podcast A Incubadora! Este é o Episódio 62, e como vocês já sabem, nosso objetivo é trazer informação atualizada e acessível para todos os profissionais de saúde que atuam com neonatologia e falam a língua portuguesa.Hoje apresentamos o Journal Club 41, com quatro artigos muito atuais e de grande relevância para a prática clínica e para a pesquisa em neonatologia.No primeiro artigo, vamos discutir o estudo “Whole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial” - https://pubmed.ncbi.nlm.nih.gov/39992674/, que avalia os efeitos da hipotermia terapêutica em recém-nascidos pré-termo tardios com encefalopatia hipóxico-isquêmica.O segundo artigo traz uma análise robusta em nível internacional: “Outcomes of Preterm Infants Born at 22 to 23 Weeks' Gestation in 11 International Neonatal Networks” - https://pubmed.ncbi.nlm.nih.gov/40853670/, que descreve desfechos de extremo prematuros em diferentes realidades ao redor do mundo.No terceiro artigo, abordamos a aplicabilidade da radiografia de tórax no cuidado diário, com o estudo “Diaphragm Position on Chest Radiograph to Estimate Lung Volume in Neonates” - https://pubmed.ncbi.nlm.nih.gov/40690243/, que investiga a posição do diafragma como marcador indireto do volume pulmonar em recém-nascidos.E, por fim, exploramos um tema que conecta epigenética e cuidado centrado na família: “Methylation of the glucocorticoid receptor gene (NR3C1) in preterm infants undergoing kangaroo mother care method” - https://www.tandfonline.com/doi/full/10.1080/28361512.2025.2545608, que avalia o impacto do método canguru sobre a metilação do gene do receptor de glicocorticoides em prematuros.Fique com a gente para conhecer os detalhes desses estudos e refletir sobre como podem influenciar a prática clínica em nossas UTIs neonatais.#PodcastAIncubadora #JournalClub #Neonatologia #CuidadosNeonatais #Prematuridade #UTINeonatal #MedicinaPerinatal #HipotermiaTerapêutica #EncefalopatiaNeonatal #PrematurosTardios #Neuroproteção #PrematurosExtremos #DesfechosNeonatais #RedesInternacionais #SobrevidaExtrema #RadiografiaDeTórax #VolumePulmonar #Diafragma #VentilaçãoNeonatal #MétodoCanguru #Epigenética #GeneNR3C1 #CuidadoCentradoNaFamília #ContatoPeleAPele  Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Jesse Selber, MD, discuss the following articles from the September 2025 issue: “Assessing the Shift: Increasing Rates of Immediate Breast Reconstruction by Nonplastic Surgeons: Insights from a Nationwide Analysis” by Kilmer, Pawly, Wehelie. Read the article for FREE: https://bit.ly/BreastReconShift Special guest, Jesse Selber, MD, was most recently the Acting Chair, the Director of Clinical Research and Professor in the Department of Plastic Surgery at the University of Texas MD Anderson Cancer Center. Currently, he is a Physician Executive and the Surgery Service Line Chief of Beaumont, where he also serves as Professor of Plastic Surgery. In this role, Dr. Selber is responsible for all surgical activities within the Beaumont System, including 8 hospitals overseeing 2000 surgeons. Dr. Selber completed surgery residency at the University of Pennsylvania and fellowship in Microvascular Reconstructive Surgery at MD Anderson Cancer Center. Dr. Selber's clinical practice is exclusively complex cancer reconstruction. He is a surgical innovator, developing numerous techniques, and author of the only robotic plastic surgery textbook.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Episode 38 of the ESCRS Eye Journal Club with Artemis Matsou, Alfredo Borgia and Victoria Till was held on August 12th 2025 The guest experts are Michael Amon and Jascha Wendelstein who discuss the following paper: Refractive, Visual, and Safety Outcomes of Three Surgical Techniques for Aphakia Correction

The September 2025 episode of the Journal Club with Justin. Plenty of clinical and scientific pearls for your practicein ED medicine... #FOAMed

Featuring an interview with Dr Erika Hamilton, including the following topics: Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract Management protocols for adverse events associated with sacituzumab govitecan (7:49) García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101. Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51) Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134. Sequencing ADCs in breast cancer (13:12) Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract CME information and select publications

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm. CME information and select publications here.

Der Sommer neigt sich dem Ende entgegen und wir sind bei unserer 80. Folge angelangt!! Diesmal gibt es neben einigen Ankündigungen und einem kurzen Refresher zum Unterdrucklungenödem zwei spannende Leitlinien, die wir euch vorstellen möchten: die S1 Leitlinie zu Hygiene in der Regionalanästhesie und die S1 Leitlinie zu Gefässzugängen im Schockraum. Ausserdem gibt es einen Beitrag zum Umgang mit Patient:innen […] Der Beitrag Hauptfolge August 2025 – Folge 80 erschien zuerst auf pin-up-docs - don't panic.

Here it is, the first of our new series called GU Cast Journal Club! A dedicated GU Cast Journal Club has been suggested by many of our listeners and viewers over the years, and we are really pleased to kick off today with the first monthly episode. And we are particularly pleased to introduce our GU Cast Journal Club Editors, Dr Carlso Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER). Declan Murphy is anchoring today's episode while Renu is busy elsewhere. Each month, two papers will be discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU OncologyThe objective is to draw attention to important papers in GU Oncology, and critique these in a robust mannerThe key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series. For this inaugural epsiode, we have selected two very important recent papers:1. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial 2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant. 

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial JAMA 2025.  Discussion by:Guest:Philip Lieberman, MDResident- Family Medicine Residency ProgramJefferson Health - Abington2. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial.  New England Journal of Medicine 2025 Discussion by:Guest:Donna Ryan, MDProfessor Emerita at Pennington Biomedical Baton Rouge, LA, USA3. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial. Alzheimer's Research & Therapy.  Discussion by:Guest:Kathryn Donnelly, DOResident– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Send us a textBom-vindos ao episódio 61 do Podcast A Incubadora. Esse é o nosso Journal Club 40 – Especial Agosto Dourado. A cada quinze dias, trazemos uma seleção de artigos recentes em neonatologia para discussão em português, com o objetivo de tornar a literatura científica mais acessível para profissionais da área.Neste episódio, vamos conversar sobre quatro estudos que exploram diferentes dimensões do leite humano no cuidado neonatal:Potential Epigenetic Effects of Human Milk on Infants' Neurodevelopment - https://www.mdpi.com/2072-6643/15/16/3614Effect of Neonatal Unit Interventions Designed to Increase Breastfeeding in Preterm Infants: An Overview of Systematic Reviews - https://karger.com/neo/article/121/4/411/896932/Effect-of-Neonatal-Unit-Interventions-Designed-toSeverity of Bronchopulmonary Dysplasia in Infants Born Extremely Preterm and Randomized to Early Human Milk Fortification with a Donor Milk-Derived Fortifier for Two Weeks - https://www.jpeds.com/article/S0022-3476(25)00291-4/abstractNon-nutritional Use of Human Milk as a Therapeutic Agent in Neonates: Brain, Gut, and Immunologic Targets - https://pubmed.ncbi.nlm.nih.gov/39348773/ Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Join us for the August edition of the Simulcast Journal Club, recorded live at the Australasian Simulation Congress 2025 in Adelaide:   Vic was joined by guest Adam Montagu , Ellen Davies and Parick Frost to discuss two papers relevant to the work being done at Adelaide Health Simulation  Davies, E., Crawford, L., Crawford, T. et al. Capturing and cultivating the simulated patient/participant (SP) experience: a qualitative study exploring how the perspectives of SPs can inform the co-production of an orientation resource guide. Adv Simul 10, 14 (2025)  Davies, E., Montagu, A. & Brazil, V. Recommendations for embedding simulation in health services. Adv Simul 8, 23 (2023).    Some upcoming conferences and courses  VSA Translational SIMposium (Northern Health 17 October) https://vicsim.org/component/eventbooking/vsa-event/victorian-translational-simposium  Douglas Starship Simulation Advanced Workshop (Courtesy of Erin Carn-Bennett)  S3 conference in Singapore – Ben is speaking!  Taryn Taylor comes to Bond University - Primed for Insight: Simulation to explore teams and culture    Another great month on Simulcast.  Happy listening    

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue: “Interfacility Competition and Its Impact on Cost of Carpal Tunnel Release” by Rivedal, Cichocki, Tong, et al. Read the article for FREE: https://bit.ly/CostofCarpal Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

Send us a textIf we don't learn to work with LLMs now, we might end up competing with them.

Send us a textWhole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.Faix RG, Laptook AR, Shankaran S, Eggleston B, Chowdhury D, Heyne RJ, Das A, Pedroza C, Tyson JE, Wusthoff C, Bonifacio SL, Sánchez PJ, Yoder BA, Laughon MM, Vasil DM, Van Meurs KP, Crawford MM, Higgins RD, Poindexter BB, Colaizy TT, Hamrick SEG, Chalak LF, Ohls RK, Hartley-McAndrew ME, Dysart K, D'Angio CT, Guillet R, Kicklighter SD, Carlo WA, Sokol GM, DeMauro SB, Hibbs AM, Cotten CM, Merhar SL, Bapat RV, Harmon HM, Sewell E, Winter S, Natarajan G, Mosquera R, Hintz SR, Maitre NL, Benninger KL, Peralta-Carcelen M, Hines AC, Duncan AF, Wilson-Costello DE, Trembath A, Malcolm WF, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA Pediatr. 2025 Apr 1;179(4):396-406. doi: 10.1001/jamapediatrics.2024.6613.PMID: 39992674 Free PMC article. Clinical Trial.EBNEO Commentary: Is Therapeutic Hypothermia Beneficial to Infants Born Between 33 and 35 Weeks Gestation?Spahic H, Zoubovsky SP, Dietz RM.Acta Paediatr. 2025 Jul;114(7):1742-1743. doi: 10.1111/apa.70098. Epub 2025 Apr 18.PMID: 40251839 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textFenton Third-Generation Growth Charts of Preterm Infants Without Abnormal Fetal Growth: A Systematic Review and Meta-Analysis.Fenton TR, Elmrayed S, Alshaikh BN.Paediatr Perinat Epidemiol. 2025 Jun 19. doi: 10.1111/ppe.70035. Online ahead of print.PMID: 40534585 Review.Birth weight and head circumference for 22-29 weeks gestation neonates from an international cohort.Fenton TR, Alshaikh B, Kusuda S, Helenius K, Modi N, Norman M, Lui K, Lehtonen L, Battin M, Klinger G, Vento M, Lastrucci V, Gagliardi L, Adams M, Marba STM, Isayama T, Hakansson S, Bassler D, Shah PS; International Network for Evaluation of Outcomes (iNeo) of Neonates Investigators.Arch Dis Child Fetal Neonatal Ed. 2025 Jun 19;110(4):401-408. doi: 10.1136/archdischild-2024-327845.PMID: 39762001Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textRetinopathy of Prematurity and Risk of Structural Brain Abnormalities on Magnetic Resonance Imaging at Term Among Infants Born at Less Than or Equal to 32 Weeks of Gestation.Roy S, Peterson L, Kline-Fath B, Parikh NA; Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS) Investigators.J Pediatr. 2025 Jun 27;286:114711. doi: 10.1016/j.jpeds.2025.114711. Online ahead of print.PMID: 40582695 Free article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textDeferred Cord Clamping With High Oxygen in Extremely Preterm Infants: A Randomized Clinical Trial.Katheria AC, Ines F, Lee HC, Sollinger C, Vali P, Morales A, Sanjay S, Dorner R, Koo J, Gollin Y, Das A, Poeltler D, Steinhorn R, Finer N, Lakshminrusimha S.JAMA Pediatr. 2025 Jul 21:e252128. doi: 10.1001/jamapediatrics.2025.2128. Online ahead of print.PMID: 40690234Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textEarly Neurodevelopment of Extremely Preterm Infants Administered Autologous Cord Blood Cell Therapy: Secondary Analysis of a Nonrandomized Clinical Trial.Zhou L, Razak A, McDonald CA, Yawno T, McHugh DT, Whiteley G, Connelly K, Sackett V, Miller SL, Jenkin G, Novak I, Hunt RW, Malhotra A.JAMA Netw Open. 2025 Jul 1;8(7):e2521158. doi: 10.1001/jamanetworkopen.2025.21158.PMID: 40608334 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textDiaphragm Position on Chest Radiograph to Estimate Lung Volume in Neonates.Dahm SI, Sett A, Gunn EF, Ramanauskas F, Hall R, Stewart D, Koeppenkastrop S, McKenna K, Gardiner RE, Rao P, Tingay DG.JAMA Pediatr. 2025 Jul 21:e252108. doi: 10.1001/jamapediatrics.2025.2108. Online ahead of print.PMID: 40690243 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textImpact of Sedation on Ventilator-Induced Diaphragmatic Dysfunction in Extremely Preterm Infants.Hoshino Y, Arai J, Hirono K, Maruo K, Miura-Fuchino R, Yukitake Y, Kajikawa D, Kamakura T, Hinata A, Okada Y, Sato Y.Pediatr Pulmonol. 2025 May;60(5):e71126. doi: 10.1002/ppul.71126.PMID: 40365938Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textThis week on Journal Club, we review five important studies with direct implications for your work in the NICU. First, we examine the newly released third-generation Fenton growth charts—how do they differ from previous versions, and what do they reveal about how we may have underestimated early growth trajectories in preterm infants? Next, we evaluate the association between retinopathy of prematurity and structural brain abnormalities on term-equivalent MRI—can ROP severity serve as a marker for broader neurologic vulnerability? We also look at a randomized trial assessing the safety and effectiveness of using 100% oxygen during deferred cord clamping in extremely preterm infants. Does this strategy safely reduce early hypoxemia without increasing the risk of hyperoxia? Then, we explore early neurodevelopmental outcomes following autologous cord blood stem cell infusions in preterm infants—what signals are emerging, and how close are we to bedside applications? Finally, we unpack two diaphragm-focused investigations: one challenging the long-held practice of using rib counts on chest radiographs to estimate lung volumes, and another showing how even short-term sedation can induce measurable diaphragmatic dysfunction. These studies raise important questions—how should we adapt our practice in light of this data? Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Featuring an interview with Dr Jacob Sands, including the following topics: TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00) Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52) Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599. Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500. Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26) Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11. CME information and select publications

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue: “Improving Patient Transfer Quality: A Retrospective Study on a Transfer Center for a Canadian Upper Extremity Revascularization Program” by Arsenault, Efanov, Lavoie, et al. Read the article for FREE: https://bit.ly/TransferQuality Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to discuss a new retrospective cohort study by Rahimy et al. The panel explores how obstructive sleep apnea impacts the progression of diabetic retinopathy and elevates the risk for systemic vascular events such as stroke, heart attack, and death. With nearly 24,000 patients analyzed, the study sheds light on the importance of screening and managing comorbidities in patients with nonproliferative diabetic retinopathy—and raises critical questions about what role retina specialists should play in addressing them.

Drs. Kat Talcott and Sarwar Zahid join for a journal club episode. FA Image Generation (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2835600)Industry Trial Sponsorship and Results (https://www.ajo.com/article/S0002-9394(25)00325-3/fulltext)GLP-1 Agonists and Neovascular AMD (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2834964)Burnout Among Uveitis Specialists (https://www.ajo.com/article/S0002-9394(25)00342-3/abstract)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Send us a textNesta edição quinzenal do Podcast A Incubadora, as apresentadoras Mariana e Marôla trazem informação acessível, atualizada e em português para profissionais de neonatologia, com a análise crítica de quatro artigos recentes e relevantes para a prática clínica e a pesquisa.No Journal Club 39, discutimos:1. Quantitative lung ultrasound to guide surfactant retreatment in preterm neonates born at ≤30 weeks' gestation – estudo multicêntrico retrospectivo que avalia o uso da ultrassonografia pulmonar quantitativa para orientar a necessidade de nova dose de surfactante. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00309-3/fulltext 2. Unbound bilirubin and risk of severe neurodevelopmental impairment in extremely low birthweight newborns– investigação sobre a associação entre bilirrubina não conjugada e risco de comprometimento grave do neurodesenvolvimento em recém-nascidos com peso extremamente baixo. https://pmc.ncbi.nlm.nih.gov/articles/PMC12284093/3. Bridging healthcare gaps: a scoping review on the role of artificial intelligence, deep learning, and large language models in alleviating problems in medical deserts – revisão que explora como a inteligência artificial e modelos de linguagem podem ajudar a reduzir desigualdades no acesso à saúde em áreas carentes. https://academic.oup.com/pmj/article-abstract/101/1191/4/7775387?redirectedFrom=fulltext4. Fenton Third-Generation Growth Charts of Preterm Infants Without Abnormal Fetal Growth: A Systematic Review and Meta-Analysis – revisão sistemática e meta-análise sobre as curvas de crescimento de terceira geração de Fenton para prematuros sem crescimento fetal anormal. https://onlinelibrary.wiley.com/doi/10.1111/ppe.70035Aproveita mais esse episódio do Journal Club, que conecta evidências científicas ao cuidado cotidiano na neonatologia. Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Featuring perspectives from Dr Benjamin Levy, including the following topics: Introduction: The Boards (0:00) Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43) Immunotherapy for Metastatic NSCLC (24:41) Antibody-Drug Conjugates (33:46) Novel Bispecific Antibodies (42:08) Journal Club with Dr Levy (51:28) CME information and select publications

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue: “Toe Transfers Outperform Replantation after Digit Amputations: Outcomes of 126 Toe Transfers” by Lo and Wei. Read the article for FREE: https://bit.ly/126ToeTransfers Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Podcast Summary This episode of the Pain Exam Podcast, hosted by Dr. David Rosenblum, discusses an interesting article about Ketorolac injections for musculoskeletal conditions. The podcast covers: Ketorolac is an NSAID that provides analgesic and anti-inflammatory effects through inhibition of prostaglandin synthesis Multiple studies comparing Ketorolac injections to corticosteroids and hyaluronic acid for various conditions Research shows Ketorolac injections are equally effective as corticosteroids for subacromial conditions, adhesive capsulitis, carpal-metacarpal joint issues, and hip/knee osteoarthritis Ketorolac may be a safer alternative to steroids for certain patients, though it has its own contraindications for those with renal, gastrointestinal, or cardiovascular disease Dr. Rosenblum considers the potential of using Ketorolac injections directly at pain sites rather than intramuscularly Upcoming Courses and Conferences Ultrasound courses in New York and Costa Rica (check unwrappedpain.org) Private ultrasound sessions available Dr. Rosenblum will be speaking at Pain Week about ultrasound in pain practice and PRP Presenting at a primary care conference in London Teaching ultrasound at ISPN LAPSES conference in Chile (Dr. Rosenblum won't attend this year) Ketorolac Injections: An Effective Alternative for Musculoskeletal Pain Management Musculoskeletal conditions such as bursitis, adhesive capsulitis, and osteoarthritis affect millions and often require injectable therapies to reduce pain and inflammation. Traditionally, corticosteroid injections have been the mainstay treatment. However, concerns over side effects like tendon rupture, cartilage damage, and systemic hyperglycemia have prompted exploration of alternatives. A recent narrative review by Kiel et al. (2024) highlights ketorolac—a parenteral nonsteroidal anti-inflammatory drug (NSAID)—as a promising substitute for corticosteroids in musculoskeletal injections. Warning: OFF Label use of Ketorolac discussed. Please consult your physician. See full article  for details. Subacromial Ketorolac Injections for Shoulder Pain Subacromial bursitis and impingement syndrome are common causes of shoulder pain and disability. Several randomized controlled trials have shown that subacromial ketorolac injections provide pain relief and functional improvement comparable to corticosteroids: Goyal et al. demonstrated significant reductions in pain scores after subacromial injection of 60 mg ketorolac versus 40 mg methylprednisolone, with no difference in outcomes between groups. Taheri et al. found similar short-term pain relief at 1 and 3 months with either ketorolac or corticosteroid subacromial injections. Kim et al. reported equivalent clinical improvement in rotator cuff syndrome patients receiving ketorolac or triamcinolone injections. Min et al. noted ketorolac led to better forward flexion and patient satisfaction at 4 weeks compared to corticosteroids. These studies support ketorolac as an effective agent for subacromial injection, offering an alternative for patients where corticosteroid use is limited. Intra-articular Ketorolac Injections for Adhesive Capsulitis and Osteoarthritis Adhesive capsulitis (frozen shoulder) and osteoarthritis of the hip, knee, and carpometacarpal joint are often treated with intra-articular corticosteroids. Ketorolac injections have shown comparable efficacy in these conditions: Akhtar et al. found intra-articular ketorolac significantly reduced shoulder pain at 4 weeks in adhesive capsulitis compared to hyaluronic acid. Ahn et al. reported similar pain relief between intra-articular ketorolac and corticosteroid injections in adhesive capsulitis, with ketorolac providing superior shoulder mobility at 3 and 6 months. Koh et al. showed that adding ketorolac to hyaluronic acid injections in carpometacarpal osteoarthritis resulted in faster onset of pain relief compared to hyaluronic acid alone. Park et al. observed equivalent functional improvements with intra-articular ketorolac or corticosteroids in hip osteoarthritis. Jurgensmeier et al. demonstrated similar symptom improvement at 1 and 3 months post-injection for ketorolac and triamcinolone in hip and knee osteoarthritis. Xu et al. and Bellamy et al. confirmed ketorolac's comparable pain relief and functional benefits to corticosteroids for knee osteoarthritis, with ketorolac being more cost-effective. Lee et al. noted quicker pain reduction with intra-articular ketorolac combined with hyaluronic acid versus hyaluronic acid alone in knee osteoarthritis. aSafety and Pharmacologic Considerations Ketorolac's anti-inflammatory action stems from cyclooxygenase inhibition, reducing prostaglandin synthesis. Its half-life is approximately 5.2–5.6 hours, and it is metabolized in the liver. Unlike corticosteroids, ketorolac avoids systemic hyperglycemia and cartilage damage risks. Animal and in vitro studies suggest ketorolac may protect cartilage by inhibiting inflammatory cytokines. While gastrointestinal, renal, and cardiovascular risks associated with NSAIDs remain considerations, localized intra-articular and subacromial ketorolac injections may limit systemic exposure and adverse effects. Mild, transient post-injection pain has been reported but resolves without intervention. Conclusion Ketorolac injections, administered intra-articularly or subacromially, are a safe, effective, and economical alternative to corticosteroids for managing common musculoskeletal conditions. Their comparable efficacy in reducing pain and improving function, combined with a more favorable side effect profile, makes ketorolac an appealing option for clinicians and patients alike. Further research is warranted to fully elucidate long-term safety and optimal dosing strategies. FAQS Ketorolac Injections for Musculoskeletal Conditions: Frequently Asked Questions Musculoskeletal pain from conditions like bursitis, adhesive capsulitis, and osteoarthritis often requires injectable treatments. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is emerging as a promising alternative to corticosteroids. Below are common questions and answers based on a recent narrative review by Kiel et al. (2024). 1. What is ketorolac and how does it work? Ketorolac is a parenteral NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes, which decreases prostaglandin synthesis. It can be administered orally, intramuscularly, intravenously, or by injection directly into joints or around bursae. 2. How effective is ketorolac for musculoskeletal conditions? Studies show ketorolac injections provide significant pain relief and functional improvement comparable to corticosteroids in conditions like: Subacromial bursitis and shoulder impingement (subacromial injections) Adhesive capsulitis (frozen shoulder) (intra-articular injections) Osteoarthritis of the hip, knee, and thumb carpometacarpal joint (intra-articular injections) 3. What evidence supports subacromial ketorolac injections? Randomized controlled trials found: Goyal et al. and Taheri et al. reported similar pain reduction and functional outcomes between ketorolac and corticosteroids for subacromial injections. Kim et al. and Min et al. observed comparable or better patient satisfaction and shoulder mobility with ketorolac versus corticosteroids. 4. How does intra-articular ketorolac compare to corticosteroids for adhesive capsulitis? Akhtar et al. showed ketorolac reduced shoulder pain more than hyaluronic acid. Ahn et al. found ketorolac and corticosteroids equally effective for pain relief, with ketorolac providing better shoulder mobility at 3 and 6 months. 5. What about ketorolac for osteoarthritis? Ketorolac combined with hyaluronic acid provided faster pain relief than hyaluronic acid alone in thumb carpometacarpal joint osteoarthritis (Koh et al.). Intra-articular ketorolac had similar efficacy to corticosteroids in hip (Park et al., Jurgensmeier et al.) and knee osteoarthritis (Bellamy et al., Xu et al.). Ketorolac injections were more cost-effective compared to corticosteroids (Bellamy et al.). 6. Are ketorolac injections safe? Ketorolac's side effects are similar to other NSAIDs, mainly involving gastrointestinal, renal, and cardiovascular risks. However, localized intra-articular and subacromial injections may reduce systemic exposure. Animal studies suggest ketorolac does not harm cartilage and may protect against inflammatory damage. Mild, transient local pain post-injection is possible but usually resolves without treatment. 7. What are the limitations of ketorolac use? Ketorolac is not suitable for patients with: Renal impairment Gastrointestinal ulcers or bleeding risk Cardiovascular disease or hypertension NSAID hypersensitivity, especially in asthma or chronic urticaria patients Clinicians should assess individual risks before choosing ketorolac injections. 8. How does ketorolac's pharmacokinetics affect its use? Ketorolac has a plasma half-life of about 5.2 to 5.6 hours and is metabolized in the liver. Pharmacokinetics for subcutaneous or intra-articular administration are less defined but systemic absorption occurs. Its relatively short half-life supports repeated dosing if needed. 9. Why consider ketorolac over corticosteroids? Ketorolac avoids corticosteroid-associated risks such as tendon rupture, cartilage damage, and steroid-induced hyperglycemia. It is also more cost-effective, making it a favorable option for patients and healthcare systems. 10. What further research is needed? More large-scale, long-term studies are needed to fully understand ketorolac's intra-articular effects, optimal dosing, and safety profile compared to corticosteroids and other treatments. Summary: Ketorolac injections, whether intra-articular or subacromial, offer a safe, effective, and economical alternative to corticosteroids for managing various musculoskeletal conditions. This makes ketorolac an important option in pain management and inflammation control.     Reference: Kiel J, Applewhite AI, Bertasi TGO, Bertasi RAO, Seemann LL, Costa LMC, Helmi H, Pujalte GGA. Ketorolac Injections for Musculoskeletal Conditions: A Narrative Review. Clinical Medicine & Research. 2024;22(1):19-27. DOI: https://doi.org/10.3121/cmr.2024.1847 Disclaimer: This Podcast, website and any content from NRAP Academy (PMRexam.com) otherwise known as Qbazaar.com, LLC is  for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.    

Los artículos que se tratan en el episodio de hoy están listados aquí: Associations of Bronchopulmonary Dysplasia and Infection with School-Age Brain Development in Children Born Preterm.Kim C, Ufkes S, Guo T, Chau V, Synnes A, Grunau RE, Miller SP.J Pediatr. 2025 Jun;281:114524. doi: 10.1016/j.jpeds.2025.114524. Epub 2025 Feb 27. PMID: 40023219.Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants: A Meta-Analysis.Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J.JAMA Pediatr. 2025 May 27:e251025. doi: 10.1001/jamapediatrics.2025.1025. Online ahead of print.PMID: 40423988 Occurrence and Time of Onset of Intraventricular Hemorrhage in Preterm Neonates: A Systematic Review and Meta-Analysis of Individual Patient Data.Nagy Z, Obeidat M, Máté V, Nagy R, Szántó E, Veres DS, Kói T, Hegyi P, Major GS, Garami M, Gasparics Á, Te Pas AB, Szabó M.JAMA Pediatr. 2025 Feb 1;179(2):145-154. doi: 10.1001/jamapediatrics.2024.5998.PMID: 39786414  Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comSíguenos en nuestras redes:Twitter: @incubadorapodInstagram: @laincubadorapodcast Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. CME information and select publications here.

Featuring an interview with Dr Erika Hamilton, including the following topics: Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00) Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract  Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025. First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02) Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109. Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06) Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53) Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019. Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104. Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004. CME information and select publications

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue:   “Toe Transfers Outperform Replantation after Digit Amputations: Outcomes of 126 Toe Transfers” by Lo and Wei.   “Improving Patient Transfer Quality: A Retrospective Study on a Transfer Center for a Canadian Upper Extremity Revascularization Program” by Arsenault, Efanov, Lavoie, et al.   “Interfacility Competition and Its Impact on Cost of Carpal Tunnel Release” by Rivedal, Cichocki, Tong, et al.   Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.   READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Send us a textEarly full enteral nutrition with fortified milk in very preterm infants: a randomized clinical trial.Salas AA, Gunawan E, Jeffcoat S, Nguyen K.Am J Clin Nutr. 2025 May;121(5):1117-1123. doi: 10.1016/j.ajcnut.2025.02.019. Epub 2025 Feb 21.PMID: 39986385 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textExtended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, Sánchez PJ, Goldberg RN, D'Angio CT, Van Meurs KP, Hibbs AM, Ambalavanan N, Cosby SS, Newman NS, Vohr BR, Walsh MC, Das A, Ohls RK, Fuller J, Rysavy MA, Ghavam S, Brion LP, Puopolo KM, Moore R, Baack ML, Colaizy TT, Baserga M, Osman AF, Merhar SL, Poindexter BB, DeMauro SB, Kumar V, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA. 2025 Jun 24;333(24):2154-2163. doi: 10.1001/jama.2025.5791.PMID: 40294395 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!